PT20 is a novel iron-based phosphate binder, that has the potential to treat patients with hyperphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease (CKD).
- PT20 is exclusively licensed from United Kingdom Research and Innovation (formerly the Medical Research Council) in the United Kingdom.
- Patents protect PT20 out to 2029. An additional five-year supplementary protection is expected to be granted upon approval in Europe, extending patent protection to 2034. The same is likely to apply in the US.
- PT20 has successfully completed one pivotal study and now requires one further pivotal study after which regulatory filings for marketing approval would be expected to follow.